Vivani's Losses Widen Amid R&D Push; Cash Dwindles

TL;DR

**VANI is burning cash fast with widening losses, making its GLP-1 implant a high-stakes bet for survival.**

AI Summary

Vivani Medical, Inc. (VANI) reported a net loss of $7.144 million for the three months ended June 30, 2025, an increase from $5.356 million in the same period of 2024. For the six months ended June 30, 2025, the net loss widened to $13.446 million from $11.395 million in the prior year. Research and development expenses increased to $8.976 million for the six months ended June 30, 2025, up from $7.239 million in 2024, reflecting increased clinical trial activities. General and administrative expenses also rose to $5.044 million from $4.669 million over the same six-month period. The company's cash and cash equivalents significantly decreased to $6.794 million as of June 30, 2025, from $18.352 million at December 31, 2024. Total assets declined to $28.905 million from $41.561 million, while total stockholders' equity plummeted to $4.910 million from $17.610 million. Vivani is prioritizing its NPM-139 semaglutide implant program for chronic weight management, with clinical development expected to begin in 2026, following positive preclinical data showing approximately 20% weight loss maintained for over six months.

Why It Matters

Vivani's escalating net losses and rapidly declining cash reserves are a critical concern for investors, signaling a heightened need for future financing to sustain operations and advance its drug implant pipeline. The strategic shift to prioritize NPM-139, a semaglutide implant, positions Vivani in the highly competitive GLP-1 market, directly challenging established players like Novo Nordisk (NVO) with Wegovy. Success in clinical trials could offer a differentiated product with improved adherence, benefiting patients and potentially disrupting the market. However, employees face uncertainty given the significant cash burn and the long, costly road to commercialization, while customers await innovative solutions for chronic disease management.

Risk Assessment

Risk Level: high — Vivani's cash and cash equivalents decreased by over 60% from $18.352 million at December 31, 2024, to $6.794 million at June 30, 2025. The company reported a net loss of $13.446 million for the six months ended June 30, 2025, and net cash used in operating activities was $11.250 million, indicating a significant burn rate that could necessitate further dilutive financing.

Analyst Insight

Investors should exercise extreme caution and monitor Vivani's cash position closely. Given the substantial cash burn and widening losses, potential investors should await further clarity on financing plans and significant positive clinical milestones for NPM-139 before considering an investment.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

$28.905M

total Debt

Not Disclosed

net Income

-$7.144M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$6.794M

revenue Growth

Not Disclosed

Key Numbers

• $7.144M — Net loss for Q2 2025 (Increased from $5.356M in Q2 2024)
• $13.446M — Net loss for H1 2025 (Increased from $11.395M in H1 2024)
• $6.794M — Cash and cash equivalents as of June 30, 2025 (Decreased from $18.352M at Dec 31, 2024)
• $8.976M — Research and development expenses for H1 2025 (Increased from $7.239M in H1 2024)
• $4.910M — Total stockholders' equity as of June 30, 2025 (Decreased from $17.610M at Dec 31, 2024)
• 59,243,903 — Shares of common stock outstanding as of August 12, 2025 (Reflects current share count)
• 20% — Weight loss achieved by NPM-139 in preclinical study (Maintained for over six months in rats)
• $11.250M — Net cash used in operating activities for H1 2025 (Indicates significant cash burn)

Key Players & Entities

• Vivani Medical, Inc. (company) — registrant
• Okava Pharmaceuticals, Inc. (company) — animal health partner
• U.S. Food and Drug Administration (regulator) — cleared IND for NPM-119
• Cortigent, Inc. (company) — wholly owned subsidiary for neurostimulation assets
• Second Sight Medical Products, Inc. (company) — legacy company merged with NPM
• Nano Precision Medical, Inc. (company) — merged with Second Sight
• The NASDAQ Capital Market (regulator) — exchange where VANI is registered
• Novo Nordisk (company) — competitor in GLP-1 market

FAQ

Risk Factors

• Significant cash burn and limited cash reserves [high — financial]: The company's cash and cash equivalents decreased to $6.794 million as of June 30, 2025, from $18.352 million at December 31, 2024. Net cash used in operating activities for H1 2025 was $11.250 million, indicating a substantial burn rate that could impact future operations and development timelines.
• Dependence on successful clinical development and regulatory approval [high — operational]: Vivani is heavily reliant on the success of its NPM-139 semaglutide implant program. Delays or failures in clinical trials, or inability to secure regulatory approval, could materially impact the company's future prospects and financial viability.
• Deteriorating financial position [high — financial]: Total stockholders' equity has plummeted to $4.910 million as of June 30, 2025, from $17.610 million at December 31, 2024. This significant decline, coupled with increasing net losses, raises concerns about the company's long-term financial health.
• Evolving regulatory landscape for weight management therapies [medium — regulatory]: The market for weight management therapies is subject to evolving regulatory scrutiny and requirements. Changes in FDA or other regulatory body guidelines could impact the development, approval, and commercialization of Vivani's products.
• Intense competition in the obesity and weight management market [medium — market]: The obesity and weight management market is highly competitive, with established pharmaceutical companies and emerging biotechs developing various therapeutic approaches. Vivani faces competition from existing treatments and pipeline candidates.
• Reliance on third-party manufacturers and suppliers [medium — operational]: The company's ability to manufacture and supply its products may depend on third-party manufacturers and suppliers. Any disruptions in this supply chain could impact product availability and market penetration.

Industry Context

Vivani Medical operates in the highly competitive and rapidly evolving obesity and weight management market. This sector is characterized by significant investment in novel therapeutic approaches, including GLP-1 receptor agonists, which have shown considerable efficacy. The market is driven by increasing rates of obesity globally and a growing demand for effective, long-term solutions. However, it also faces intense competition from established pharmaceutical giants and emerging biotechs, as well as scrutiny regarding long-term safety and accessibility.

Regulatory Implications

Vivani's success hinges on navigating the complex regulatory pathways for drug approval, particularly with the FDA. The development of NPM-139 will require rigorous clinical trials to demonstrate safety and efficacy. Any delays, setbacks in trials, or changes in regulatory requirements for weight management therapies could significantly impact the company's timeline and ability to bring its product to market.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress for NPM-139.
2. Assess cash burn rate and future financing needs.
3. Evaluate competitive landscape and market penetration strategies.
4. Track regulatory developments and potential approval timelines.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported net loss of $7.144 million and cash reserves of $6.794 million, reflecting increased R&D expenses and a significant cash burn.
• 2025-06-30: End of H1 2025 — Net loss widened to $13.446 million, with R&D expenses at $8.976 million and G&A at $5.044 million. Stockholders' equity decreased substantially to $4.910 million.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents stood at $18.352 million and total stockholders' equity at $17.610 million, providing a baseline for current period declines.
• 2026: Expected commencement of clinical development for NPM-139 — This is a critical milestone for the company's lead product candidate, with positive preclinical data suggesting significant weight loss maintenance.

Glossary

NPM-139

Vivani Medical's lead product candidate, a semaglutide implant for chronic weight management. (This is the company's primary focus for future revenue generation, and its development progress is key to investor valuation.)

Semaglutide

A glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and chronic weight management. (Understanding the therapeutic class of NPM-139 helps contextualize its market potential and competitive landscape.)

Preclinical data

Research and testing conducted before human clinical trials, typically involving laboratory studies and animal models. (The positive preclinical data for NPM-139 is a key driver of the company's development strategy and investor optimism, though it precedes human efficacy and safety validation.)

Stockholders' Equity

The residual interest in the assets of an entity after deducting all its liabilities. It represents the net worth of the company. (The significant decline in stockholders' equity from $17.610 million to $4.910 million indicates a substantial erosion of the company's net worth.)

Year-Over-Year Comparison

Vivani Medical's financial performance in the first half of 2025 shows a deteriorating financial position compared to the prior year. Net losses have widened, with the six-month period ending June 30, 2025, reporting a loss of $13.446 million, up from $11.395 million in the same period of 2024. Research and development expenses have increased, reflecting investment in clinical activities, while cash reserves have been significantly depleted, falling from $18.352 million at the end of 2024 to $6.794 million. Total stockholders' equity has also seen a sharp decline, underscoring the increased financial strain on the company.

Key Financial Figures

• $0.0001 — h Registered Common Stock , par value $0.0001 per share VANI The NASDAQ Capital M

Filing Documents

• vani-20250630.htm (10-Q) — 1322KB
• ex311_1.htm (EX-31.1) — 18KB
• ex312_2.htm (EX-31.2) — 12KB
• ex321_3.htm (EX-32.1) — 12KB
• 0001753926-25-001330.txt ( ) — 7460KB
• vani-20250630_def.xml (EX-101.DEF) — 305KB
• vani-20250630_pre.xml (EX-101.PRE) — 450KB
• vani-20250630_cal.xml (EX-101.CAL) — 55KB
• vani-20250630_lab.xml (EX-101.LAB) — 705KB
• vani-20250630.xsd (EX-101.SCH) — 55KB
• vani-20250630_htm.xml (XML) — 1201KB

Financial Statements (unaudited)

Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for each three month period ended during the six months ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33

SIGNATURES

SIGNATURES 34 1 PART I. FINANCIAL STATEMENTS Item 1. Financial Statements VIVANI MEDICAL, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) (In thousands, except per share data) June 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 6,794 $ 18,352 R&D tax credit incentive receivable 494 253 Prepaid expenses and other current assets 1,427 1,837 Total current assets 8,715 20,442 Property and equipment, net 1,577 1,693 Operating lease right-of-use assets, net 17,146 17,957 Restricted cash 1,338 1,338 Deposits and other assets 129 131 TOTAL ASSETS $ 28,905 $ 41,561 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 1,762 $ 817 Accrued expenses 1,586 1,803 Litigation accrual 1,675 1,675 Accrued compensation expense 356 343 Lease liability, current portion 1,337 1,348 Total current liabilities 6,716 5,986 Lease liability, noncurrent portion 17,279 17,965 TOTAL LIABILITIES 23,995 23,951 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, par value $ 0.0001 per share; 10,000 shares authorized; none outstanding - - Common stock, par value $ 0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 59,244 and 59,235 at June 30, 2025 and December 31, 2024 , respectively 6 6 Additional paid-in capital 140,193 139,480 Accumulated other comprehensive income 81 48 Accumulated deficit ( 135,370 ) ( 121,924 ) TOTAL STOCKHOLDERS' EQUITY 4,910 17,610 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 28,905 $ 41,561 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 VIVANI MEDICAL, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (unaudited) (In thousands, except per share data) Three Months Ended June 3

View Full Filing

View this 10-Q filing on SEC EDGAR